Alnylam Pharmaceuticals and Eli Lilly are competing in the biopharmaceutical market, with high trading volume driving market coverage by MarketBeat.

The entities involved

• Alnylam Pharmaceuticals →

  biopharmaceutical company

  • Orna Therapeutics was acquired by Eli Lilly and Company, a development within the RNA therapeutics sector.Mon 15:43
• Eli Lilly and Company →

  American pharmaceutical company

  • Trade data and legislative control are currently influencing market sentiment and corporate operations.Sat 00:04
  • Agreement between Eli Lilly and Hims & Hers Health expands access to Lilly's medicines.Fri 14:13
• MarketBeat →

  American personal finance blog

  • MarketBeat reported consensus ratings and target prices for Deep Fission Inc., which received a strong-buy rating from Benchmark.Fri 23:44
  • Several financial firms, including Raymond James Financial and Truist Financial, issued multiple rating and price target updates on November 6, 2026.Fri 22:59

Related events

• Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Jun 18
• Alnylam Pharmaceuticals and Oncocyte are being compared for investment, and MarketBeat reports analyst ratings for Oncocyte.Oct 21
• Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Sep 23
• MarketBeat listed Eli Lilly and Company among stocks to watch on October 31, 2026.Oct 31
• Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.Jun 8